The multi-kinase inhibitor foretinib (1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide) has been tested, in combination with lapatinib, in a phase Ib trial that enrolled 19 patients with advanced HER2+ BC. Here, ERBB2 is linked to breast cancer.